Moderna 2022 Priorities and Capital Allocation

Safety and reactogenicity are similar between .211 and 1273 boosters Solicited reactogenicity (through day 7) 100 Solicited local adverse reactions Solicited systemic adverse reactions 100- 75- 50- 25- Any Local Pain 50 μg mRNA-1273 50 μg mRNA-1273.211 50 µg mRNA-1273 50 μg mRNA-1273.211 Erythema 50 μg mRNA-1273 50 μg mRNA-1273.211 Swelling Grade 1 50 μg mRNA-1273 50 μg mRNA-1273.211 50 μg mRNA-1273 50 μg mRNA-1273.211 Lymphadenopathy Slide 18 75- 50- 25- 0 Any Systemic Grade 2 50 μg mRNA-1273 50 μg mRNA-1273.211 Fever 50 μg mRNA-1273 50 μg mRNA-1273.211 Headache 50 µg mRNA-1273 50 μg mRNA-1273.211 Fatigue 50 μg mRNA-1273 50 μg mRNA-1273.211 Myalgia Grade 3 50 μg mRNA-1273 50 μg mRNA-1273.211 Arthralgia 50 μg mRNA-1273 50 μg mRNA-1273.211 Nausea/ vomiting 50 μg mRNA-1273 50 μg mRNA-1273.211 Chills 50 μg mRNA-1273 50 μg mRNA-1273.211 Safety summary The reactogenicity profile was similar between the two booster vaccines (.211 n=298, 1273 n=167) The frequency and types of unsolicited adverse events were also comparable, with no serious events in the .211 group up to 28 days after the booster dose (.211 N=300, 1273 N=171) moderna

View entire presentation